Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review

Table 3 Diagnostic efficiencies of circulating lncRNAs in gastric cancer

Circulating lncRNA	Species	Samples	Sensitivity	Specificity	AUC	Population
FER1L4[190]	Human	Plasma	67.2%	80.3%	0.778	83 GCs (Pre- and post-operative patients)
H19[178]	Human	Plasma	74%	58%	0.64	43 GCs and 34 healthy controls
CUDR, LSINCT-5 and PTENP1[193]	Human	Serum	74.1% of CUDR + LSINCT-5 + PTENP1 for GC detection,	100% of CUDR + LSINCT-5 + PTENP1 for GC detection, 97.0% of CUDR + LSINCT-5 + PTENP1 for early GC detection	0.92 of CUDR + LSINCT-5 + PTENP1 for GC detection, 0.832 of CUDR + LSINCT-5 + PTENP1 for early GC detection	9 early-stage GCs, 64 advanced-stage GCs, 15 benign Peptic ulcer patients and 86 healthy controls
			77.8% of CUDR + LSINCT-5 + PTENP1 for early GC detection
LINC00152[189]	Human	Plasma	48.1%	85.2%	0.657	79 GCs and 81 healthy controls

When a combination of circulating lncRNAs is characterized, a (+) is included between the listed circulating lncRNAs. AUC: Area under the curve; GC: Gastric cancer.